GC Medical Science Corporation (KOSDAQ:142280)
South Korea · Delayed Price · Currency is KRW 3,325.00
-35.00 (-1.04%)
At close: Oct 2, 2026
GC Medical Science Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 79,677 | 87,076 | 77,711 | 100,562 | 121,856 | 152,316 | |
Market Cap Growth | -7.57% | 12.05% | -22.72% | -17.47% | -20.00% | -53.95% |
Enterprise Value | 96,730 | 110,168 | 105,347 | 119,151 | 134,083 | 193,496 |
Last Close Price | 3325.00 | 4005.00 | 3580.00 | 4770.00 | 5780.00 | 7230.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 23.75 | 21.70 | 55.95 | - | - |
Forward PE | - | 34.24 | 34.24 | 34.24 | 34.24 | 34.24 |
PS Ratio | 0.78 | 0.80 | 0.75 | 1.07 | 1.08 | 1.50 |
PB Ratio | 1.42 | 1.88 | 1.79 | 2.72 | 3.42 | 4.01 |
P/TBV Ratio | 1.50 | 2.00 | 1.92 | 2.98 | 3.72 | 4.27 |
P/FCF Ratio | 10.86 | 35.17 | 174.54 | - | 16.35 | - |
P/OCF Ratio | 9.53 | 12.10 | 21.23 | 23.71 | 11.20 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.95 | 1.02 | 1.01 | 1.27 | 1.19 | 1.90 |
EV/EBITDA Ratio | 15.21 | 16.16 | 17.42 | 23.25 | 58.33 | - |
EV/EBIT Ratio | 40.85 | 38.16 | 46.60 | 93.70 | - | - |
EV/FCF Ratio | 13.19 | 44.50 | 236.61 | - | 17.99 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.27 | 0.38 | 0.40 | 0.61 | 0.66 | 0.98 |
Debt / EBITDA Ratio | 2.39 | 2.56 | 2.87 | 4.41 | 10.18 | - |
Debt / FCF Ratio | 2.08 | 7.05 | 38.98 | - | 3.14 | - |
Net Debt / Equity Ratio | 0.27 | 0.37 | 0.38 | 0.46 | 0.36 | 0.93 |
Net Debt / EBITDA Ratio | 2.35 | 2.51 | 2.76 | 3.29 | 5.50 | -2.15 |
Net Debt / FCF Ratio | 2.04 | 6.90 | 37.45 | -12.11 | 1.70 | -1.61 |
Asset Turnover | 1.01 | 1.22 | 1.16 | 1.00 | 1.18 | 1.01 |
Inventory Turnover | 4.51 | 5.19 | 5.35 | 5.38 | 4.68 | 3.78 |
Quick Ratio | 0.77 | 0.61 | 0.50 | 0.58 | 0.80 | 0.47 |
Current Ratio | 1.47 | 1.15 | 1.06 | 0.93 | 1.27 | 1.07 |
Return on Equity (ROE) | -4.00% | 7.71% | 8.45% | 5.17% | -8.31% | -43.99% |
Return on Assets (ROA) | 1.47% | 2.02% | 1.58% | 0.85% | -1.18% | -12.53% |
Return on Invested Capital (ROIC) | 3.48% | 4.67% | 3.97% | 2.49% | -2.98% | -27.85% |
Return on Capital Employed (ROCE) | 3.70% | 5.20% | 4.40% | 2.90% | -3.20% | -43.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.71% | 4.21% | 4.61% | 1.79% | -2.94% | -13.92% |
FCF Yield | 9.20% | 2.84% | 0.57% | -1.38% | 6.12% | -14.31% |
Buyback Yield / Dilution | -2.85% | 0.26% | 0.06% | -26.96% | -0.05% | - |